Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Nicum · SciRah

Researcher profile · Semantic Scholar

S. Nicum

Share profile

S. Nicum — researcher profile on SciRah

h-index: 17
Works: 69
Citations: 2,482

Most-cited papers

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. Coleman, G. Fleming, M. Brady, E. Swisher +28 more
2019New England Journal of Medicine749 citations Open access
Semantic Scholar
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N. Colombo, C. Sessa, A. du Bois, J. Ledermann +43 more
2019Annals of Oncology644 citations Open access
Semantic Scholar
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
K. N. Moore, A. Angelergues, G. Konecny, Yolanda García +26 more
2023New England Journal of Medicine361 citations Open access
Semantic Scholar
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J. Mateo, Victor Moreno, Avinash Gupta, S. Kaye +14 more
2016Targeted oncology132 citations Open access
Semantic Scholar
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
A. Olawaiye, L. Gladieff, David M. O'Malley, Jae-Weon Kim +40 more
2025The Lancet60 citations
Semantic Scholar
British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024.
Esther L. Moss, A. Taylor, Adrian Andreou, Christine Ang +28 more
2024European Journal of Obstetrics, Gynecology, and Reproductive Biology43 citations Open access
Semantic Scholar
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
K. Haldar, K. Gaitskell, A. Bryant, Heather O. Dickinson +3 more
2009Cochrane Database of Systematic Reviews33 citations Open access
Semantic Scholar
Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Liz Y. Han, V. Karavasilis, T. VanHagen, S. Nicum +7 more
2010European Journal of Cancer31 citations
Semantic Scholar
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Marcia Hall, H. Dehbi, Susana Banerjee, R. Lord +10 more
2020Gynecologic Oncology28 citations Open access
Semantic Scholar
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
D. O'Malley, T. Myers, P. Wimberger, T. van Gorp +12 more
2024Future Oncology25 citations Open access
Semantic Scholar
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
S. Sundar, R. Manchanda, C. Gourley, A. George +17 more
2021International Journal of Gynecological Cancer25 citations Open access
Semantic Scholar
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
S. Nicum, N. McGregor, Rachel Austin, L. Collins +11 more
2024British Journal of Cancer24 citations Open access
Semantic Scholar
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
O. Elyashiv, J. Ledermann, G. Parmar, L. Farrelly +11 more
2020International Journal of Gynecological Cancer24 citations Open access
Semantic Scholar
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
Joyce F. Liu, S. Nicum, P. Reichardt, K. Croitoru +5 more
2018Gynecologic Oncology22 citations Open access
Semantic Scholar
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation
J. Mateo, M. Friedlander, C. Sessa, K. Leunen +6 more
201321 citations
Semantic Scholar
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
R. Morgan, A. Clamp, Bethany M. Barnes, K. Timms +22 more
2023International Journal of Gynecological Cancer20 citations Open access
Semantic Scholar
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells
Mara Artibani, K. Masuda, Zhi-Yuan Hu, Pascal C Rauher +27 more
2021JCI Insight18 citations Open access
Semantic Scholar
Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.
L. Molife, J. Mateo, T. McGoldrick, M. Krebs +16 more
201218 citations
Semantic Scholar
A source of hope for platinum-resistant ovarian cancer?
S. Blagden, S. Nicum
2021The Lancet17 citations
Semantic Scholar
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
Anita Mansouri, N. McGregor, R. Dunn, Samuel Dobbie +3 more
2020BMJ Open15 citations Open access
Semantic Scholar
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
C. Roberts, V. Strauss, Sylwia Kopijasz, C. Gourley +9 more
2019British Journal of Cancer15 citations Open access
Semantic Scholar
DNA-repair pathway inhibitors for the treatment of ovarian cancer
I. Martinek, K. Haldar, K. Gaitskell, A. Bryant +3 more
2010Cochrane Database of Systematic Reviews14 citations Open access
Semantic Scholar
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
S. Nicum, C. Roberts, L. Boyle, Sylwia Kopijasz +7 more
2014BMC Cancer13 citations Open access
Semantic Scholar
Angiogenesis inhibitors for the treatment of ovarian cancer
K. Gaitskell, I. Martinek, Andrew Bryant, Sean Kehoe +2 more
2011Cochrane Database of Systematic Reviews13 citations Open access
Semantic Scholar
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
A. Olawaiye, Jae-Weon Kim, A. Bagameri, Erin Bishop +16 more
2024Journal of Gynecologic Oncology12 citations Open access
Semantic Scholar
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer
S. Sundar, A. Nordin, J. Morrison, N. Wood +29 more
2023Cancers12 citations Open access
Semantic Scholar
722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
S. Nicum, Jane Holmes, N. McGregor, R. Dunn +12 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Avinash Gupta, V. Moreno, E. Dean, Y. Drew +10 more
201211 citations
Semantic Scholar
VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
R. Coleman, G. Fleming, M. Brady, E. Swisher +16 more
2019Annals of Oncology10 citations Open access
Semantic Scholar
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.
L. Steventon, E. Kipps, K. Man, R. Roylance +8 more
2024European Journal of Cancer9 citations Open access
Semantic Scholar
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
R. Morgan, C. Ferreras, I. Peset, E. Avizienyte +9 more
2022BMC Medicine9 citations Open access
Semantic Scholar
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
F. Kazmi, S. Nicum, R. Roux, L. Spiers +7 more
2021Clinical Cancer Research7 citations Open access
Semantic Scholar
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic
Alexandra Taylor, S. Sundar, R. Bowen, Rick Clayton +16 more
2021International Journal of Gynecological Cancer7 citations Open access
Semantic Scholar
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer
L. Steventon, K. Man, S. Nicum, Rowan E Miller +7 more
2024The Oncologist6 citations Open access
Semantic Scholar
Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
L. Steventon, S. Nicum, Pinkie Chambers, K. Man +5 more
2025European Journal of Cancer5 citations Open access
Semantic Scholar
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael, William Wilson, S. Sunshine, N. Annels +11 more
2024International Journal of Gynecological Cancer5 citations
Semantic Scholar
Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK
S. Oxley, A. Kalra, M. Sideris, N. Itzkowitz +17 more
2023Cancers5 citations Open access
Semantic Scholar
OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
S. Nicum, V. Strauss, N. McGregor, I. McNeish +4 more
20175 citations Open access
Semantic Scholar
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
K. Haldar, K. Gaitskell, Andrew Bryant, S. Nicum +2 more
2011Cochrane Database of Systematic Reviews4 citations Open access
Semantic Scholar
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population
E. Merry, R. Kesmez, Tamara Yu, Michael J. Flynn +7 more
2024International Journal of Gynecological Cancer3 citations Open access
Semantic Scholar
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
K. El-Shakankery, Joanna Kefas, K. Palmer, A. Houston +12 more
2024Cancers2 citations Open access
Semantic Scholar
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
S. Nicum, S. Blagden
2022Clinical Cancer Research2 citations Open access
Semantic Scholar
Prospective Multicentre Evaluation Of Secondary Cytoreductive Surgery In The Era Of PARP-Inhibitors (CONCEPT) In Relapsed Epithelial Ovarian Cancer
C. Fotopoulou, Shriya Varghese, Carole Cummins, S. Nicum +1 more
2025International Journal of Gynecological Cancer1 citations
Semantic Scholar
#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
D. Lorusso, A. Bagameri, Erin Bishop, Anita Chudecka-Głaz +16 more
2023Poster/ePoster Sessions1 citations Open access
Semantic Scholar
#1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial
Kathleen N. Moore, D. Berton, G. Konecny, S. Nicum +16 more
2023Oral Sessions1 citations Open access
Semantic Scholar
METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).
M. Hall, Hakim-Moulay Debhi, S. Nicum, R. Lord +7 more
20181 citations
Semantic Scholar
TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A. Michael, R. Lord, G. Hall, L. Hanna +13 more
20161 citations
Semantic Scholar
METRO-BIBF Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide (MCy) with and without nintedanib in advanced ovarian cancer (AOC)
M. Hall, R. Lillywhite, S. Nicum, R. Lord +3 more
20161 citations Open access
Semantic Scholar
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
S. Nicum, C. Brooks, R. Wharton, L. Boyle +10 more
20131 citations
Semantic Scholar
Determination of the rates of neurological toxicity associated with the use of dose-dense (DD) paclitaxel-containing schedules in patients with early breast cancer
S. Nicum, S. Sutherland, Ie Smith, S. Ashley +1 more
20081 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. McNeish×8
Invite
I. McNeish — researcher profile on SciRah
C. Gourley×8
Invite
C. Gourley — researcher profile on SciRah
A. Clamp×8
Invite
A. Clamp — researcher profile on SciRah
R. Glasspool×7
Invite
R. Glasspool — researcher profile on SciRah

×7

Invite

D. Lorusso — researcher profile on SciRah

Invite

S. Kaye — researcher profile on SciRah

Invite

M. Hall — researcher profile on SciRah

Invite

J. Morrison — researcher profile on SciRah

J. Ledermann×6

Invite

J. Ledermann — researcher profile on SciRah

Invite

A. Oaknin — researcher profile on SciRah

C. Fotopoulou×5

Invite

C. Fotopoulou — researcher profile on SciRah

Invite

A. Hackshaw — researcher profile on SciRah